U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07158411) titled 'Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)' on Aug. 28.
Brief Summary: The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Intervention:
DRUG: Vimseltinib
Administer...